Provincial/Territorial Perspective Drug Shortages: BC and Beyond

Transcription

1 Provincial/Territorial Perspective Drug Shortages: BC and Beyond Elaine Chong, British Columbia Ministry of Health 2017 CADTH Symposium April 24, 2017

2 Overview Collaborative Context Provincial/Territorial Drug Shortages Task Team British Columbia Initiatives Case Studies Discussion and Questions 2

3 Acknowledgements British Columbia Ministry of Health Ms. Darlene Arenson Ms. Barbara Walman Manitoba Health, Provincial Drug Programs Ms. Joan Blakley Ms. Bernadette Preun PT Drug Shortages Task Team Colleagues Health Canada Mr. Michael Carter Mr. Ed Morgan 3

4 TIER 1 Anticipated Actual TIER 2 TIER 3 Actual with Greatest Potential Impact 4

5 Collaborative Context Multi-Stakeholder Steering Committee on Drug Shortages (MSSC) Manitoba is the current Provincial/Territorial Co-Chair British Columbia was the previous Co-Chair 5

6 Provincial/Territorial Drug Shortages Task Team Formed in 2012 Mandate: to help identify, prevent, alleviate, and resolve drug shortage situations that have a significant effect on public health 6

7 Provincial/Territorial Drug Shortages Task Team Share, develop, negotiate, and deliver P/T intergovernmental plans, projects, strategies and initiatives on drug shortages Strategic analysis, expertise, and advice to P/T Executives, Deputy Ministers, and Ministers 7

8 Provincial/Territorial Drug Shortages Task Team Collaborate with the federal government (primarily Health Canada and the Public Health Agency of Canada) and non-governmental organizations to address and resolve drug shortages 8

9 Provincial/Territorial Drug Shortages Task Team Manitoba is the current chair British Columbia was the previous chair (2014 to 2016) Membership includes P/T Ministries of Health, regional health authorities or hospitals, as well as procurement agencies 9

10 Provincial/Territorial Drug Shortages Task Team Core Responsibilities Communicate, identify, track, respond Escalate Collaborate Meetings by teleconference every 2 weeks Input into 10

11 55 RESOLVED National Drug Shortages ACTIVE National Drug Shortages 5 11 ONGOING National Drug Shortages Sept 2014 Aug

12 15 RESOLVED National Drug Shortages ACTIVE National Drug Shortages 14 5 ONGOING National Drug Shortages Sept 2016 Mar

13 British Columbia Initiatives Collaboration with stakeholders (e.g., BCPhA) Recognition of need to make drug shortage information more accessible Increased frequency and duration of shortages Rapid changes and multiple sources of information Limited avenues to communicate changes in real-time 13

14 British Columbia Initiatives Provincial Drug Shortages Web Page: Publicly available Reported and confirmed BC-specific drug shortages Temporary PharmaCare coverage of alternatives Current and resolved shortages Updated each business day Searchable and sortable 14

15 Case Study #1 MELPHALAN 15

16 Melphalan Nitrogen mustard-derivative alkylating agent Bone marrow transplantation Sole supplier in Canada (Aspri Pharma) 16

17 Melphalan Timeframes for shortage Scope Key steps: local, P/T Task Team, Health Canada Health Canada Special Access Programme eligibility Action and resolution/outcome Lessons learned 17

18 Case Study #2 CLOBAZAM 18

19 Clobazam 1,5-benzodiazepine with a long duration of action Seizure disorders Generic and brand suppliers (Apotex, Teva, Pro Doc, Lundbeck) Apotex has majority of market share 19

20 Clobazam Timeframes for shortage Scope Multi-stakeholder engagement Key steps: local, P/T Task Team, Health Canada Action and resolution/outcome Lessons learned 20

21 DISCUSSION AND QUESTIONS 21

22 Elaine Chong, PharmD, BCPS Previous Chair, Provincial/Territorial Drug Shortages Task Team Director, Decision Support and Evaluation Guidance Drug Intelligence and Optimization Medical Beneficiary and Pharmaceutical Services Division British Columbia Ministry of Health 22